Eosinophilia in Dermatologic Disorders

Immunology and Allergy Clinics of North America

Volumn 35, Issue 3, 2015, Pages 545-560

  de Graauw, Elisabeth ^a,b   Beltraminelli, Helmut ^a   Simon, Hans Uwe ^b   Simon, Dagmar ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atopic dermatitis; Cutaneous lymphoma; Drug hypersensitivity reaction; Eosinophilic dermatitis; Eosinophils; Hypereosinophilic syndromes

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; CALCINEURIN INHIBITOR; CD52 ANTIBODY; CELL ANTIBODY; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 5 ANTIBODY; IVERMECTIN; PERMETHRIN; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SULFONAMIDE; TIABENDAZOLE; UNCLASSIFIED DRUG; CYTOKINE;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLISTER; BULLOUS PEMPHIGOID; CELL INFILTRATION; CLINICAL FEATURE; CUTANEOUS LARVA MIGRANS; DIAGNOSTIC PROCEDURE; DRESS SYNDROME; ECZEMA; EOSINOPHIL; EOSINOPHILIA; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; PAPULE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCABIES; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN DISEASE; SKIN FIBROSIS; SKIN INFECTION; SKIN NODULE; SKIN TUMOR; URTICARIA; CYTOLOGY; FIBROSIS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; SKIN; SKIN DISEASES;

CYTOKINES; EOSINOPHILIA; EOSINOPHILS; FIBROSIS; HUMANS; INFLAMMATION; SKIN; SKIN DISEASES;

EID: 84937730849     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.05.005     Document Type: Review

References (80)

1. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325.
2. Leiferman K.M., Gleich G.J., Peters M.S. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:415-441.
3. Simon D., Simon H.U., Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy 2013, 68:409-416.
4. Yousefi S., Simon D., Simon H.U. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 2012, 24:736-739.
5. Roth N., Städler S., Lemann M., et al. Distinct eosinophil cytokine expression patterns in skin diseases - the possible existence of functionally different eosinophil subpopulations. Allergy 2011, 66:1477-1486.
6. Simon D., Hoesli S., Roth N., et al. Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol 2011, 127:194-199.
7. Morshed M., Yousefi S., Stöckle C., et al. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 2012, 67:1127-1137.
8. Leiferman K.M., Ackerman S.J., Sampson H.A., et al. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 1985, 313:282-285.
9. Cheng J.F., Ott N.L., Peterson E.A., et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997, 99:683-692.
10. Peters M.S., Schroeter A.L., Gleich G.J. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol 1983, 109:141-148.
11. Soragni A., Yousefi S., Stoeckle C., et al. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell 2015, 57(6):1011-1021.
12. Simon D., Aeberhard C., Erdemoglu Y., et al. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 2014, 69:125-131.
13. Foster E.L., Simpson E.L., Fredrikson L.J., et al. Eosinophils increase neuron branching in human and murine skin and in vitro. PLoS One 2011, 6:22029.
14. Schneider L., Tilles S., Lio P., et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013, 131:295-299.
15. Kiehl P., Falkenberg K., Vogelbruch M., et al. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 2001, 145:720-729.
16. Simon D., Vassina E., Yousefi S., et al. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004, 114:887-895.
17. Simon D., Hösli S., Kostylina G., et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008, 121:122-128.
18. Martin S.F., Esser P.R., Weber F.C., et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011, 66:1152-1163.
19. Nakashima C., Otsuka A., Kitoh A., et al. Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis. J Allergy Clin Immunol 2014, 134:100-107.
20. Wozel G. Eosinophile Dermatosen. Hautarzt 2007, 58:347-360.
21. Walton S.F., Oprescu F.I. Immunology of scabies and translational outcomes: identifying the missing links. Curr Opin Infect Dis 2013, 26:116-122.
22. Heukelbach J., Feldmeier H. Epidemiological and clinical characteristics of hookworm-related cutaneous larva migrans. Lancet Infect Dis 2008, 8:302-309.
23. Veraldi S., Persico M.C., Francia C., et al. Chronic hookworm-related cutaneous larva migrans. Int J Infect Dis 2013, 17:277-279.
24. Gilmore S.J. Control Strategies for Endemic Childhood Scabies. PLoS One 2011, 6:15990.
25. Ionescu M.A., Rivet J., Daneshpouy M., et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 2005, 52:32-94.
26. Jawed S.I., Myskowski P.L., Horwitz S., et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. J Am Acad Dermatol 2014, 70:205.
27. Wilcox R.A. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014, 89:837-851.
28. Simon H.U., Plötz S.G., Dummer R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112-1120.
29. Simon H.U., Plötz S.G., Simon D., et al. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol 2001, 124:242-245.
30. Egeler R.M., van Halteren A.G., Hogendoorn P.C., et al. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev 2010, 234:213-232.
31. Demoly P., Adkinson N.F., Brockow K., et al. International consensus on drug allergy. Allergy 2014, 69:420-437.
32. Husain Z., Reddy B.Y., Schwartz R.A. DRESS syndrome: part II. management and therapeutics. J Am Acad Dermatol 2013, 68:709.
33. Acharya K.R., Ackerman S.J. Eosinophil granule proteins: form and function. J Biol Chem 2014, 289:17406-17415.
34. Arsenovic N., Sheehan L., Clark D., et al. Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis. J Forensic Leg Med 2010, 17:57-61.
35. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69:868-887.
36. Cugno M., Marzano A.V., Asero R., et al. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010, 5:97-101.
37. Moossavi M., Mehregan D.R. Wells' syndrome: a clinical and histopathologic review of seven cases. Int J Dermatol 2003, 42:62-67.
38. Simon H.U., Rothenberg M.E., Bochner B.S., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
39. Gleich G.J., Schroeter A.L., Marcoux J.P., et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984, 310:1621-1626.
40. Khoury P., Herold J., Alpaugh A., et al. Episodic angioedema with eosinophilia (Gleich's syndrome) is a multilineage cell cycling disorder. Haematologica 2015, 100(3):300-307.
41. Ambros-Rudolph C.M., Müllegger R.R., Vaughan-Jones S.A., et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006, 54:395-404.
42. Valent P., Escribano L., Broesby-Olsen S., et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014, 69:1267-1274.
43. Ishida M., Iwai M., Kagotani A., et al. Cutaneous mastocytosis with abundant eosinophilic infiltration: a case report with review of the literature. Int J Clin Exp Pathol 2014, 7:2695-2697.
44. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
45. Daniel B.S., Murrell D.F., Borradori L. Bullous pemphigoid: therapeutic algorithm and practical management. Expert Opin Orphan Drugs 2013, 1:405-412.
46. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet 2013, 381:320-332.
47. Di Zenzo G., della Torre R., Zambruno G., et al. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol 2012, 30:3-16.
48. Nishie W. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci 2014, 73:179-186.
49. Ronaghy A., Streilein R.D., Hall R.P. Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). J Dermatol Sci 2014, 74:93-94.
50. Ruocco V., Ruocco E., Lo Schiavo A., et al. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 2013, 31:374-381.
51. Zaraa I., Sellami A., Bouguerra C., et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study. J Eur Acad Dermatol Venereol 2011, 25:1160-1167.
52. Jean-Baptiste S., O'Toole E.A., Chen M., et al. Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clin Exp Immunol 2002, 127:470-478.
53. Conte M.I., Pescatore A., Paciolla M., et al. Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease. Hum Mutat 2014, 35:165-177.
54. Nervi S.J., Schwartz R.A., Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol 2006, 55:285-289.
55. Katoh M., Nomura T., Miyachi Y., et al. Eosinophilic pustular folliculitis: a review of the Japanese published works. J Dermatol 2013, 40:15-20.
56. Fujiyama T., Tokura Y. Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis. J Dermatol 2013, 40:419-423.
57. Weigelt N., Metze D., Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010, 37:578-586.
58. Simpson R.C., Crichlow S., Harman K.E. Pigmented facial plaques. Granuloma faciale (GF). Clin Exp Dermatol 2010, 35:805-806.
59. Gauger A., Ronet C., Schnopp C., et al. High local interleukin 5 production in granuloma faciale (eosinophilicum): role of clonally expanded skin-specific CD4+ cells. Br J Dermatol 2005, 153:454-457.
60. Greco A., Rizzo M.I., De Virgilio A., et al. Churg-Strauss syndrome. Autoimmun Rev 2015, 14(4):341-348.
61. Buder K., Ruppert S., Trautmann A., et al. Angiolymphoid hyperplasia with eosinophilia and Kimura's disease - a clinical and histopathological comparison. J Dtsch Dermatol Ges 2014, 12:224-228.
62. Kempf W., Pfaltz K., Vermeer M.H., et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011, 118:4024-4035.
63. Wilcox R.A. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management. Am J Hematol 2015, 90:73-76.
64. Kusam S., Toney L.M., Sato H., et al. Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J Immunol 2003, 170:2435-2441.
65. Cerroni L., Beham-Schmid C., Kerl H. Cutaneous Hodgkin's disease: an immunohistochemical analysis. J Cutan Pathol 1995, 22:229-235.
66. Jundt F., Anagnostopoulos I., Bommert K., et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999, 94:2065-2071.
67. Aldinucci D., Gloghini A., Pinto A., et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
68. Farber M.J., La Forgia S., Sahu J., et al. Eosinophilic dermatosis of hematologic malignancy. J Cutan Pathol 2012, 39:690-695.
69. Pinal-Fernandez I., Selva-O'Callaghan A., Grau J.M. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014, 13:379-382.
70. French L.E., Dziadzio L., Kelly E.A., et al. Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol 2003, 90:452-455.
71. Kreuter A. Localized scleroderma. Dermatol Ther 2012, 25:135-147.
72. Hertzman P.A., Blevins W.L., Mayer J., et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990, 322:869-873.
73. Simon D., Simon H.U. Eosinophilic disorders. J Allergy Clin Immunol 2007, 119:1291-1300.
74. Valent P., Klion A.D., Rosenwasser L.J., et al. ICON: eosinophil disorders. World Allergy Organ J 2012, 5:174-181.
75. Wechsler M.E., Fulkerson P.C., Bochner B.S., et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 2012, 130:563-571.
76. Radonjic-Hoesli S., Valent P., Klion A.D., et al. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol 2015, 55:633-656.
77. Beck L.A., Thaçi D., Hamilton J.D., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014, 371:130-139.
78. Plötz S.G., Simon H.U., Darsow U., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003, 349:2334-2339.
79. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
80. de Masson A., Guitera P., Brice P., et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014, 170:720-724.